Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
5 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06926868 | A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | recruiting | Phase 2 / Phase 3 | 600 | Bristol-Myers SquibbINDUSTRY | 28 | Aug 10, 2026 | clinicaltrials |
| NCT05443126 | A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies | recruiting | Phase 1 / Phase 2 | 265 | Ellipses PharmaINDUSTRY | 8 | Jul 1, 2026 |
| clinicaltrials |
| NCT07647198 | FATIMA Trial: EGCG and Vitamin D3 for Prevention of Fibroid Recurrence(FATIMA) | recruiting | Phase 2 | 240 | Sheikh Shakhbout Medical CityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05565378 | A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer | active not recruiting | Phase 2 | 351 | GlaxoSmithKlineINDUSTRY | 22 | Jun 15, 2026 | clinicaltrials |
| NCT03879174 | Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation(Pembro) | unknown | Phase 2 | 25 | Mediclinic Middle EastINDUSTRY | 1 | Mar 18, 2019 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials